PIRS - Pieris Pharmaceuticals GAAP EPS of -$0.07 beats by $0.05 revenue of $10.99M misses by $0.31M

Pieris Pharmaceuticals press release (NASDAQ:PIRS): Q1 GAAP EPS of -$0.07 beats by $0.05. Revenue of $10.99M (-29.7% Y/Y) misses by $0.31M. "Pieris and our partners have made steady progress across the pipeline over the past quarter, and we are reiterating guidance on both cinrebafusp alfa phase 2 data in HER2-high gastric cancer in 2023 and PRS-220 clinical initiation this year. With IND acceptance for PRS-344/S095012, enrollment continues as planned and, separately, we are expecting an IND filing for PRS-342/BOS-342 in the next 12 months. At the same time, geopolitical and pandemic-driven challenges are affecting enrollment on certain programs. We are announcing a heightened risk to maintaining current guidance on reporting topline results for PRS-060/AZD1402 this year, despite AstraZeneca's continued commitment to execute on this program. Additionally, more time is needed for the enrollment of the HER2-low arm for cinrebafusp alfa. Notwithstanding these challenges, with our efficient program funding strategies and

For further details see:

Pieris Pharmaceuticals GAAP EPS of -$0.07 beats by $0.05, revenue of $10.99M misses by $0.31M